These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity.
    Author: Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Morisaki T, Uchida T.
    Journal: J Pharm Pharmacol; 2011 Mar; 63(3):362-8. PubMed ID: 21749383.
    Abstract:
    OBJECTIVES: The aim of this study was to prepare poly(lactide-co-glycolide) (PLGA) microspheres containing ONO-1301, a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity, with 10% of drug released in the initial burst and a sustained-release period of about 3 weeks after administration. The effect of PLGA type (molecular weight and the lactide/glycolide (L/G) ratio in PLGA), the preparative conditions and the particle size on the in-vitro release profile were examined. The effect of optimized ONO-1301-loaded PLGA microspheres on delayed nerve condition velocity (NCV) was investigated in streptozotocin (STZ) induced diabetic rats. METHODS: ONO-1301 PLGA microspheres were produced by the oil-in-water emulsion/solvent evaporation method. Drug release from the prepared microspheres was monitored in phosphate buffer solution at 37°C for 4 weeks by high-performance liquid chromatography. The in-vivo study was performed in STZ-induced diabetic rats treated with optimized ONO-1301 PLGA microspheres (10 mg/kg by intramuscular or subcutaneous injection every 3 weeks). NCV was measured in the thigh 4, 8 and 12 weeks after induction. KEY FINDINGS: The molecular weights of PLGA, the L/G ratio in PLGA and the particle diameter all affected the length of the sustained release period. Drug release from microspheres containing PLGA 5050 (MW 50,000, L/G 50/50), with an average diameter of about 30 µm, could be sustained for 3 weeks in vitro. In the in-vivo study, delayed NCV was significantly increased by treatment with these ONO-1301 PLGA microspheres once every 3 weeks, in comparison with vehicle only. CONCLUSION: Local intramuscular injection of sustained-release ONO-1301 PLGA microspheres improved delayed NCV in STZ-induced diabetic rats.
    [Abstract] [Full Text] [Related] [New Search]